Do BRAF inhibitors select for populations with different disease progression kinetics?

Table 1 Different evidences of rapid progression disease after BRAF inhibitors treatment

Experience	Patients sample (n)	Percentage of patients with a rapid disease progression kinetics
BRIM-2 [3]	39	41%
BRIM-3 [4]	42	52%
Ascierto et al. [5]	28	43%
Ackerman et al. [6]	32	50%
Italian ipilimumab EAP [2]	54	41%
Fisher et al. [7]	42	38%

ISSN: 1479-5876